Researchers have identified a range of genetic alterations that may lead to resistance to KRAS G12C inhibitors in patients ...
Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and ...
News Medical on MSN10d
Co-Occurring Mutations Drive Therapy Resistance in KRAS G12C CancersColorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic ...
Dealbreaker on MSN10d
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450 Million-Plus for Trio of Cancer DrugsClinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...
In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...
For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...
In episode four of Chat!DNA, an interview series by BGI Genomics, we feature Lin Cong, whose research on colorectal cancer, ...
KRAS driver mutations are found in greater ... cell lung cancer (NSCLC), pancreatic ductal carcinoma (PDAC), and colorectal cancer (CRC). “With this trial, we hope to bring a breakthrough ...
This South San Francisco company would be the first Bay Area biotech company to go public this year, proving that the SPAC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback